Drug Database
Back to search

Netherlands· NL-f612251eb01c

Zyclara crème 3,75%

A imiquimod product containing imiquimod, registered in Netherlands by Viatris Healthcare Limited. The same ATC class is registered in 16 of our 19 countries.

ATC D06BB10

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedZyclara crème 3,75%ATCD06BB10REGISTER NO.NL-f612251eb01cPACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about imiquimodAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Imiquimod is registered in 16 of 19 countries.

Countries holding a registration under ATC D06BB10 (imiquimod), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 10 of them publish a price we can compare per daily dose
Search imiquimod products by name

Imiquimod · ATC D06BB10

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
IMIQUIMOD
Manufacturer
Viatris Healthcare Limited
Country
Netherlands (NL)
ATC code
D06BB10
ATC class
Imiquimod
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/12/783

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

74 interactions on record for imiquimod.

Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check imiquimod against other medicinesHow interaction checks work

Imiquimod · interactions on record

74 records

  • 1 severe
  • 3 moderate
  • 70 info

Most severe, free to view

  • Aminolevulinic acidL01XD04severe
  • Porfimer sodiumL01XD01moderate
  • MethoxsalenL01XD10moderate
  • VerteporfinS01LA01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Imiquimod in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All imiquimod products

Authorised across Europe · EMA

The same active substance is authorised in 13 EEA countries. Names it is sold under:

  • Austria · Imikeraderm
  • Cyprus · Modiwart
  • Germany · Aksunim, Imikeraderm
  • Spain · Imikeraderm, Imunocare
  • United Kingdom (Northern Ireland) · Bascellex
  • Greece · Modiwart, Quimodia
  • Iceland · Aldara, Zyclara
  • Italy · Imunocare
  • Liechtenstein · Aldara, Zyclara
  • Norway · Aldara, Bascellex
  • Poland · Imikeraderm
  • Portugal · Imicare
  • Sweden · Bascellex

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/059afcc4-4c3c-4751-bee4-1622ba06ff0e
GET /v1/drugs/059afcc4-4c3c-4751-bee4-1622ba06ff0e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Crème",
  "route": "Cutaan gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/zyclara-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Imiquimod",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp110421",
  "excipients": [
    "BENZYLALCOHOL (E 1519)",
    "CETYLALCOHOL",
    "GLYCEROL (E 422)",
    "ISOSTEARINEZUUR",
    "METHYLPARAHYDROXYBENZOAAT (E 218)",
    "PARAFFINE, ZACHT (E 905)",
    "POLYSORBAAT 60 (E 435)",
    "PROPYLPARAHYDROXYBENZOAAT",
    "SORBITANMONOSTEARAAT (E 491)",
    "STEARYLALCOHOL",
    "WATER, GEZUIVERD",
    "XANTHAANGOM (E 415)"
  ],
  "substances": [
    "IMIQUIMOD"
  ],
  "leaflet_url": null,
  "authorised_at": "2012/08/23",
  "procedure_number": "EMEA/H/C/002387",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/12/783",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about imiquimod.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console